Finance

Lists
6919:TPE
Caliway Biopharmaceuticals Co Ltd
NT$79.50
-7.13%
(-6.10) 1D
Sep 11, 1:30:15 PM GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 6919...
Open
NT$84.10
High
NT$84.40
Low
NT$79.40
Mkt. cap
123.80B
Avg. vol.
9.10M
Volume
8.42M
52-wk high
NT$222.50
52-wk low
NT$75.10
EPS
-NT$0.17
Open
NT$84.10
High
NT$84.40
Low
NT$79.40
Mkt. cap
123.80B
Avg. vol.
9.10M
Volume
8.42M
52-wk high
NT$222.50
52-wk low
NT$75.10
EPS
-NT$0.17
About Caliway Biopharmaceuticals Co Ltd
CEO-
Employees-
Founded2012
Headquarters-
SectorPharmaceutical industry
Websitecaliway.com.tw
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (TWD)
-NT$0.14 / NT$2.93
-104.78%miss
Revenue / Est. (TWD)
3.57M / 6.01B
-99.94%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in TWD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in TWD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
13.42M
12.41M
2.00K
3.57M
Cost of goods sold
4.09M
3.40M
1.00K
1.24M
Cost of revenue
4.09M
3.40M
1.00K
1.24M
Research and development expenses
244.51M
112.62M
212.41M
210.66M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-33.70M
17.06M
33.42M
54.75M
Operating expense
210.81M
129.69M
245.83M
265.41M
Total operating expenses
214.89M
133.09M
245.83M
266.65M
Operating income
-201.48M
-120.68M
-245.83M
-263.08M
Other non operating income
-280.00K
9.00K
-4.00K
-2.00K
EBT including unusual items
-7.73M
80.19M
-107.75M
-222.52M
EBT excluding unusual items
-7.73M
80.19M
-107.75M
-222.52M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7.73M
80.19M
-107.75M
-222.52M
Net profit margin
-57.62%
646.17%
-5,387,700.00%
-6,239.93%
Earnings per share
-0.01
0.05
-0.07
-0.14
Interest and investment income
59.73M
85.42M
78.51M
82.27M
Interest expense
-34.00K
-22.00K
-11.00K
-329.00K
Net interest expenses
59.70M
85.40M
78.50M
81.94M
Depreciation and amortization charges
-
-
-
-
EBITDA
-195.81M
-114.79M
-239.81M
-258.15M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps